Mustang Bio, Inc. (MBIO)
NASDAQ: MBIO · Real-Time Price · USD
0.9257
-0.0317 (-3.31%)
At close: Mar 3, 2026, 4:00 PM EST
0.8712
-0.0545 (-5.89%)
Pre-market: Mar 4, 2026, 7:30 AM EST
Mustang Bio Employees
Mustang Bio had 6 employees as of December 31, 2024. The number of employees decreased by 74 or -92.50% compared to the previous year.
Employees
6
Change (1Y)
-74
Growth (1Y)
-92.50%
Revenue / Employee
n/a
Profits / Employee
-$389,167
Market Cap
6.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 6 | -74 | -92.50% |
| Dec 31, 2023 | 80 | -33 | -29.20% |
| Dec 31, 2022 | 113 | 11 | 10.78% |
| Dec 31, 2021 | 102 | 40 | 64.52% |
| Dec 31, 2020 | 62 | 11 | 21.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| Immuron | 7 |
| Alzamend Neuro | 7 |
| Can-Fite BioPharma | 5 |
| Quoin Pharmaceuticals | 5 |
| Creative Medical Technology Holdings | 4 |
| Addex Therapeutics | 2 |
MBIO News
- 8 months ago - Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga
- 8 months ago - Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - GlobeNewsWire
- 1 year ago - Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - GlobeNewsWire
- 1 year ago - Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - GlobeNewsWire
- 1 year ago - Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 1 year ago - Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewsWire
- 1 year ago - Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewsWire
- 1 year ago - Mustang Bio Announces Reverse Stock Split - GlobeNewsWire